Tuesday, December 19, 2017 3:41:43 PM
This stock was expected to be about $15 right now when the details of the Novartis deal were announced a year ago.
Since then, nothing bad has happened (except the small secondary) and all remains well. Yes, the 4 Ph2 trials did get pushed out a tiny amount (about 2 or 3 months) but for that the stock was wwwaaaayyyy overly punished.
CNAT is now only a few months away from the first results trickling in.
CNAT has now likely got tax loss selling behind it.
CNAT short interest is about 1.6mil shares - a significant number.
Look what mdgl did a week or two ago. CNAT will go up $30 in a single day if the first results are encouraging.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM